Compare · BSX vs MDLN
BSX vs MDLN
Side-by-side comparison of Boston Scientific Corporation (BSX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $60.90B.
- Over the past year, BSX is down 39.2% and MDLN is up 9.9% - MDLN leads by 49.1 points.
- MDLN has been more active in the news (5 items in the past 4 weeks vs 2 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Medline Inc.
- Price
- $62.06-5.52%
- $44.77-3.05%
- Market cap
- $60.90B
- -
- 1M return
- -11.05%
- +5.00%
- 1Y return
- -39.23%
- +9.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 5
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
- HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Latest MDLN
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)
- Large owner Cp Circle Ml Holdco Gp, Llc sold $1,070,339,440 worth of shares (26,105,840 units at $41.00) and disposed of 2,113,483 shares (SEC Form 4)